Advertisement

Impfstoffe gegen Meningokokken für das Kindesalter

  • T. TenenbaumEmail author
  • W. Hellenbrand
  • H. Schroten
Leitthema
  • 64 Downloads

Zusammenfassung

Derzeit wird von der Ständigen Impfkommission (STIKO) am Robert Koch-Institut die Verabreichung der Impfstoffe gegen Meningokokken der Serogruppen A, B, W und Y nur für Risikogruppen, die Impfung gegen Meningokokken der Serogruppe C hingegen für alle Kinder im ersten Lebensjahr empfohlen. Zwei rekombinant hergestellte proteinbasierte Meningokokken-B-Impfstoffe, der Vierkomponenten-Meningokokken-B-Impfstoff 4CMenB und ein Zweikomponentenimpfstoff mit 2 Faktor-H-Bindungsprotein(fHbp)-Varianten (rLP2086), sind in Deutschland ebenso zugelassen. Die Abdeckung der in Deutschland zirkulierenden Stämme durch diese Impfstoffe beträgt ungefähr 80 %. Der 4CMenB-Impfstoff kann in allen Altersstufen eingesetzt werden, der fHbp-Impfstoff ist nur für Adoleszente und Erwachsene zugelassen. Die mögliche universelle Implementation von MenB-Impfstoffen bei Kindern wird von der STIKO bezüglich der Epidemiologie sowie den Langzeitdaten zu Impfstoffwirksamkeit, Verträglichkeit und Effekten auf das Trägertum weiter evaluiert.

Schlüsselwörter

Neisseria meningitidis Serogruppe Immunogenität Verträglichkeit Epidemiologie 

Vaccines against meningococci for children

Abstract

Currently, the German Standing Committee on Vaccination of the Robert Koch Institute (STIKO) recommends vaccination against meningococci of serogroups A, B, W and Y only for risk groups. In contrast, vaccination against meningococci of serogroup C is recommended for all children in the first year of life. There are two recombinant protein meningococcal B (MenB) vaccines, the 4‑component vaccine 4CMenB and a 2-component vaccine including 2 variants of the factor H binding protein (fHbp; rLP2086) that are also licensed in Germany. The coverage of the circulating MenB strains of the two vaccines is approximately 80%. The 4CMenB vaccine is licensed for all age groups whereas the fHbp vaccine is licensed only for adolescents and adults. The potential universal implementation of MenB vaccines in children will be further evaluated by the STIKO in the context of the epidemiological situation and as data on long-term vaccine effectiveness and safety and effects on carriage become available.

Keywords

Neisseria meningitidis Serogroup Immunogenicity Safety Epidemiology 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

T. Tenenbaum, W. Hellenbrand und H. Schroten geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Anderson AS, Jansen KU, Eiden J (2011) New frontiers in meningococcal vaccines. Expert Rev Vaccines 10:617–634CrossRefGoogle Scholar
  2. 2.
    A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects 〉=10 to 〈26 Years of Age. https://clinicaltrials.gov/ct2/show/NCT03135834?term=bivalent&cond=Meningococcal&cntry=US&rank=3. Accessed: 26. Nov. 2018.
  3. 3.
    Atkinson B, Gandhi A, Balmer P (2016) History of Meningococcal outbreaks in the united states: implications for vaccination and disease prevention. Pharmacotherapy 36:880–892CrossRefGoogle Scholar
  4. 4.
    Bai X, Findlow J, Borrow R (2011) Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 11:969–985CrossRefGoogle Scholar
  5. 5.
    Batista RS, Gomes AP, Dutra Gazineo JL et al (2017) Meningococcal disease, a clinical and epidemiological review. Asian Pac J Trop Med 10:1019–1029CrossRefGoogle Scholar
  6. 6.
    Baxter R, Keshavan P, Welsch JA et al (2016) Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother 12:1300–1310CrossRefGoogle Scholar
  7. 7.
    Beeslaar J, Absalon J, Balmer P et al (2018) Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine 36:4004–4013CrossRefGoogle Scholar
  8. 8.
    Biolchi A, Tomei S, Santini L et al (2018) Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. Hum Vaccin Immunother.  https://doi.org/10.1080/21645515.2018.1537756 CrossRefPubMedGoogle Scholar
  9. 9.
    Boeddha NP, Schlapbach LJ, Driessen GJ et al (2018) Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-threatening Infectious Disease Study (EUCLIDS). Crit Care 22:143CrossRefGoogle Scholar
  10. 10.
    Campbell H, Edelstein M, Andrews N et al (2017) Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015–2016. Emerging Infect Dis 23:1184–1187CrossRefGoogle Scholar
  11. 11.
    Chen M, Rodrigues CMC, Harrison OB et al (2018) Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation. Sci Rep 8:12334CrossRefGoogle Scholar
  12. 12.
    Christensen H, May M, Bowen L et al (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10:853–861CrossRefGoogle Scholar
  13. 13.
    Claus H, Vogel U, De Paola R et al (2014) Meningococcal antigen typing system (MATS) based coverage for Bexsero on invasive MenB strains isolated from infants aged less than one year in Germany 2007–2013. International Pathogenic Neisseria Conference, AshevilleGoogle Scholar
  14. 14.
    Cutland CL, Nolan T, Halperin SA et al (2018) Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. Vaccine 36:1908–1916CrossRefGoogle Scholar
  15. 15.
    Dbaibo G, Tinoco Favila JC, Traskine M et al (2018) Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study. Vaccine 36:4102–4111CrossRefGoogle Scholar
  16. 16.
    De Serres G, Billard MN, Gariepy MC et al (2018) Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine.  https://doi.org/10.1016/j.vaccine.2018.10.095 CrossRefPubMedGoogle Scholar
  17. 17.
    Dhillon S, Pace D (2017) Meningococcal Quadrivalent tetanus Toxoid conjugate vaccine (MenACWY-TT; Nimenrix®): a review. Drugs 77:1881–1896CrossRefGoogle Scholar
  18. 18.
    Donnelly J, Medini D, Boccadifuoco G et al (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 107:19490–19495CrossRefGoogle Scholar
  19. 19.
    Dretler AW, Rouphael NG, Stephens DS (2018) Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Hum Vaccin Immunother 14:1146–1160CrossRefGoogle Scholar
  20. 20.
    Elias J, Harmsen D, Claus H et al (2006) Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerging Infect Dis 12:1689–1695CrossRefGoogle Scholar
  21. 21.
    Esposito S, Prymula R, Zuccotti GV et al (2014) A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother 10:2005–2014CrossRefGoogle Scholar
  22. 22.
    Findlow J, Borrow R, Snape MD et al (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51:1127–1137CrossRefGoogle Scholar
  23. 23.
    Finne J (1985) Polysialic acid—a glycoprotein carbohydrate involved in neural adhesion and bacterial meningitis. Trends Biochem Sci 10:129–132CrossRefGoogle Scholar
  24. 24.
    Fiorito TM, Bornschein S, Mihalakos A et al (2017) Rapid response to a college outbreak of meningococcal serogroup B disease: nation’s first widespread use of bivalent rLP2086 vaccine. J Am Coll Health 65:294–296CrossRefGoogle Scholar
  25. 25.
    Flacco ME, Manzoli L, Rosso A et al (2018) Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. Lancet Infect Dis 18:461–472CrossRefGoogle Scholar
  26. 26.
    Gossger N, Snape MD, Yu LM et al (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307:573–582CrossRefGoogle Scholar
  27. 27.
    Harcourt S, Morbey RA, Bates C et al (2018) Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine 36:565–571CrossRefGoogle Scholar
  28. 28.
    Harder T, Koch J, Wichmann O et al (2017) Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: systematic review. J Infect 75:81–94CrossRefGoogle Scholar
  29. 29.
    Harris SL, Donald RG, Hawkins JC et al (2017) Neisseria meningitidis Serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J 36:216–223CrossRefGoogle Scholar
  30. 30.
    Hellenbrand W, Koch J, Harder T et al (2015) Background paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 58:1314–1343CrossRefGoogle Scholar
  31. 31.
    Hoiseth SK, Murphy E, Andrew L et al (2013) A multi-country evaluation of Neisseria meningitidis Serogroup B factor H‑binding proteins and implications for vaccine coverage in different Age groups. Pediatr Infect Dis J 32:1096–1101CrossRefGoogle Scholar
  32. 32.
    https://www.bpartofit.com.au/. Accessed: 26. Nov. 2018.
  33. 33.
    Jiang H‑Q, Hoiseth SK, Harris SL et al (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086–6093CrossRefGoogle Scholar
  34. 34.
    Kent A, Beebeejaun K, Braccio S et al (2018) Safety of meningococcal group B vaccination in hospitalised premature infants. Arch Dis Child Fetal Neonatal Ed.  https://doi.org/10.1136/archdischild-2017-314152 CrossRefPubMedGoogle Scholar
  35. 35.
    Keshavan P, Pellegrini M, Vadivelu-Pechai K et al (2018) An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev Vaccines 17:865–880CrossRefGoogle Scholar
  36. 36.
    Knol MJ, Ruijs WL, Antonise-Kamp L et al (2018) Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill.  https://doi.org/10.2807/1560-7917.ES.2018.23.16.18-00158 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Knuf M, Helm K, Kolhe D et al (2018) Antibody persistence and booster response 68 months after vaccination at 2–10years of age with one dose of MenACWY-TT conjugate vaccine. Vaccine 36:3286–3295CrossRefGoogle Scholar
  38. 38.
    Köllges R, Fischbach T, Gladitz J et al (2018) Anwendung der Meningokokken-B-Impfung in Deutschland 2017. Kinder Jugendarzt 46:555–560Google Scholar
  39. 39.
    Lujan E, Winter K, Rovaris J et al (2017) Serum bactericidal antibody responses of students immunized with a Meningococcal Serogroup B vaccine in response to an outbreak on a university campus. Clin Infect Dis 65:1112–1119CrossRefGoogle Scholar
  40. 40.
    Maiden MC, Ibarz-Pavon AB, Urwin R et al (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197:737–743CrossRefGoogle Scholar
  41. 41.
    Marshall HS, Richmond PC, Beeslaar J et al (2017) Meningococcal serogroup B‑specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 17:58–67CrossRefGoogle Scholar
  42. 42.
    Martin NG, Snape MD (2013) A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 12:837–858CrossRefGoogle Scholar
  43. 43.
    Martinon-Torres F, Bernatowska E, Shcherbina A et al (2018) Meningococcal B vaccine Immunogenicity in children with defects in complement and splenic function. Pediatr.  https://doi.org/10.1542/peds.2017-4250 CrossRefGoogle Scholar
  44. 44.
    Martinon-Torres F, Carmona Martinez A, Simko R et al (2018) Antibody persistence and booster responses 24–36 months after different 4CmenB vaccination schedules in infants and children: a randomised trial. J Infect 76:258–269CrossRefGoogle Scholar
  45. 45.
    Martinon-Torres F, Salas A, Rivero-Calle I et al (2018) Life-threatening infections in children in Europe (the EUCLIDS project): a prospective cohort study. Lancet Child Adolesc Health 2:404–414CrossRefGoogle Scholar
  46. 46.
    Mcnamara LA, Thomas JD, Macneil J et al (2017) Meningococcal carriage following a vaccination campaign with menB-4C and menB-FHbp in response to a university Serogroup B Meningococcal disease outbreak-oregon, 2015–2016. J Infect Dis 216:1130–1140CrossRefGoogle Scholar
  47. 47.
    Mcquaid F, Snape MD, John TM et al (2014) Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J 33:760–766CrossRefGoogle Scholar
  48. 48.
    Mcvernon J, Nolan T, Richmond P et al (2012) A randomized trial to assess safety and Immunogenicity of alternative formulations of a Quadrivalent Meningococcal (A, C, Y, and W‑135) tetanus protein conjugate vaccine in toddlers. Pediatr Infect Dis J 31:E15–E23CrossRefGoogle Scholar
  49. 49.
    Mentzer D, Oberle D, Keller-Stanislawski B (2018) Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveill.  https://doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468 CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Muse D, Christensen S, Bhuyan P et al (2016) A phase 2, randomized, active-controlled, observer-blinded study to assess the Immunogenicity, Tolerability and safety of bivalent rLP2086, a Meningococcal Serogroup B vaccine, Coadministered with tetanus, diphtheria and Acellular pertussis vaccine and Serogroup A, C, Y and W‑135 Meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J 35:673–682CrossRefGoogle Scholar
  51. 51.
    Nainani V, Galal U, Buttery J et al (2017) An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study. Arch Dis Child.  https://doi.org/10.1136/archdischild-2017-312941 CrossRefPubMedGoogle Scholar
  52. 52.
    Ostergaard L, Lucksinger GH, Absalon J et al (2016) A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine 34:1465–1471CrossRefGoogle Scholar
  53. 53.
    Parikh SR, Andrews NJ, Beebeejaun K et al (2016) Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet 388:2775–2782CrossRefGoogle Scholar
  54. 54.
    Parikh SR, Newbold L, Slater S et al (2017) Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and quantitative assessment. Lancet Infect Dis 17:754–762CrossRefGoogle Scholar
  55. 55.
    Public Health England (2018) Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2017 to 2018. Health Protection Report 12. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/751821/hpr753818_IMD.pdf. Zugegriffen: 26. Nov. 2018Google Scholar
  56. 56.
    Read RC, Baxter D, Chadwick DR et al (2014) Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 384:2123–2131CrossRefGoogle Scholar
  57. 57.
    Richmond PC, Marshall HS, Nissen MD et al (2012) Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12:597–607CrossRefGoogle Scholar
  58. 58.
    Robert-Koch-Institut (2018) Aktualisierte Stellungnahme der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (RKI)-Stand der Bewertung einer Impfung gegen Meningokokken der Serogruppe B (Stand: 21.11.2017). Epidemiol Bull 3:35–45Google Scholar
  59. 59.
    Sadarangani M, Pollard AJ (2016) Can we control all-cause meningococcal disease in Europe? Clin Microbiol Infect 22(Suppl 5):S103–S112CrossRefGoogle Scholar
  60. 60.
    Sadarangani M, Sell T, Iro MA et al (2017) Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. CMAJ 189:E1276–E1285CrossRefGoogle Scholar
  61. 61.
    Saez-Llorens X, Aguilera Vaca DC, Abarca K et al (2015) Persistence of Meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents. Pediatr Infect Dis J 34:e264–e278CrossRefGoogle Scholar
  62. 62.
    Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM et al (2018) Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. Hum Vaccin Immunother 14:1161–1174CrossRefGoogle Scholar
  63. 63.
    Santolaya ME, O’ryan M, Valenzuela MT et al (2013) Persistence of antibodies in adolescents 18–24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 9:2304–2310CrossRefGoogle Scholar
  64. 64.
    Santolaya ME, O’ryan ML, Valenzuela MT et al (2012) Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379:617–624CrossRefGoogle Scholar
  65. 65.
    Senders S, Bhuyan P, Jiang Q et al (2016) Immunogenicity, Tolerability and safety in adolescents of bivalent rLP2086, a Meningococcal Serogroup B vaccine, Coadministered with Quadrivalent human Papilloma virus vaccine. Pediatr Infect Dis J 35:548–554CrossRefGoogle Scholar
  66. 66.
    Serra LC, York LJ, Balmer P et al (2018) Meningococcal group A, C, W, and Y tetanus Toxoid conjugate vaccine: a review of clinical data in adolescents. J Adolesc Health 63:269–279CrossRefGoogle Scholar
  67. 67.
    Snape MD, Philip J, John TM et al (2013) Bactericidal antibody persistence 2 years after immunization with 2 investigational Serogroup B Meningococcal vaccines at 6, 8 and 12 months and Immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J 32:1116–1121.  https://doi.org/10.1097/INF.0b013e31829cfff2 CrossRefPubMedGoogle Scholar
  68. 68.
    Snape MD, Saroey P, John TM et al (2013) Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 185:E715–E724CrossRefGoogle Scholar
  69. 69.
    Soeters HM, Whaley M, Alexander-Scott N et al (2017) Meningococcal carriage evaluation in response to a Serogroup B Meningococcal disease outbreak and mass vaccination campaign at a college-Rhode island, 2015–2016. Clin Infect Dis 64:1115–1122CrossRefGoogle Scholar
  70. 70.
    Study to evaluate prevention of meningococcal carriage in teenagers (SPIT). https://www.meningitis.org/research-projects/study-to-evaluate-prevention-of-meningococcal. Accessed: 26. Nov. 2018.
  71. 71.
    Takla A, Wichmann O, Koch J et al (2014) Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination. Vaccine 32:6349–6355CrossRefGoogle Scholar
  72. 72.
    Tenenbaum T, Niessen J, Schroten H (2016) Severe upper extremity dysfunction after 4CMenB vaccination in a young infant. Pediatr Infect Dis J 35:94–96PubMedGoogle Scholar
  73. 73.
    Toneatto D, Pizza M, Masignani V et al (2017) Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines 16:433–451CrossRefGoogle Scholar
  74. 74.
    Trotter CL, Andrews NJ, Kaczmarski EB et al (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–367CrossRefGoogle Scholar
  75. 75.
    Vesikari T, Esposito S, Prymula R et al (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 381:825–835CrossRefGoogle Scholar
  76. 76.
    Vesikari T, Ostergaard L, Diez-Domingo J et al (2016) Meningococcal Serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc 5:152–160CrossRefGoogle Scholar
  77. 77.
    Vesikari T, Prymula R, Merrall E et al (2015) Meningococcal serogroup B vaccine (4CMenB): booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine 33:3850–3858CrossRefGoogle Scholar
  78. 78.
    Vesikari T, Senders S, Absalon J et al (2016) Phase 3 trial of immunogenicity of bivalent rLP2086, a meningococcal serogroup B vaccine, in adolescents: bactericidal activity against a panel of antigenically diverse strains. 20th International Pathogenic Neisseria Conference, Manchester, United Kingdom, 4th–9th September 2016Google Scholar
  79. 79.
    Vesikari T, Wysocki J, Beeslaar J et al (2016) Immunogenicity, safety, and Tolerability of bivalent rLP2086 Meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and Acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatric Infect Dis Soc 5:180–187CrossRefGoogle Scholar
  80. 80.
    Vogel U, Taha MK, Vazquez JA et al (2013) Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13:416–425CrossRefGoogle Scholar
  81. 81.
    Welsch JA, Senders S, Essink B et al (2018) Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents—Results from a randomized, controlled, observer-blind phase II study. Vaccine 36:5309–5317CrossRefGoogle Scholar
  82. 82.
    Whittaker R, Dias JG, Ramliden M et al (2017) The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine 35:2034–2041CrossRefGoogle Scholar
  83. 83.
    Zlotnick GW, Jones TR, Liberator P et al (2015) The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B disease. Hum Vaccin Immunother 11:5–13CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Pädiatrische InfektiologieUniversitätsklinik für Kinder- und Jugendmedizin, Ruprecht-Karls-UniversitätMannheimDeutschland
  2. 2.Abteilung für Infektionsepidemiologie, FG 33 ImpfpräventionRobert Koch-InstitutBerlinDeutschland

Personalised recommendations